Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure

NCT ID: NCT00547638

Last Updated: 2013-08-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, prospective, randomized controlled study for the purpose of comparing DERMABOND PROTAPE to DERMABOND HVD for closure of wounds in the Emergency Department. The objective of this study is to demonstrate whether the incidence of wound closure for DERMABOND PROTAPE is equivalent to that measured for DERMABOND HVD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

According to the literature, cyanoacrylate adhesives (topical skin adhesive) have performed as intended and have not produced results that would bring into question the safety or effectiveness of cyanoacrylate adhesive for closure of surgical incisions and traumatic wounds in humans.

As such, this is a multicenter, prospective, randomized controlled study for the purpose of comparing two forms of topical skin adhesives, DERMABOND PROTAPE \& DERMABOND HVD for closure of wounds in the Emergency Department.

Patients presenting in the Emergency Department with traumatic wounds meeting the acceptance criteria will have their wounds closed with DERMABOND PROTAPE or DERMABOND HVD, and will be monitored and evaluated at 14 \& 30 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lacerations

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

laceration/wound closure topical skin adhesive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dermabond Protape

DERMABOND PROTAPE (Prineo) Topical Skin Adhesive

Group Type EXPERIMENTAL

cyanoacrylate with pressure sensitive mesh

Intervention Type DEVICE

Topical Skin Adhesive

Dermabond HVD

DERMABOND HVD Topical Skin Adhesive

Group Type ACTIVE_COMPARATOR

cyanoacrylate

Intervention Type DEVICE

Topical Skin Adhesive

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cyanoacrylate with pressure sensitive mesh

Topical Skin Adhesive

Intervention Type DEVICE

cyanoacrylate

Topical Skin Adhesive

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dermabond Protape Prineo Dermabond - HVD Dermabond - Protape

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* at least 1 year of age
* in good general health in the opinion of the Investigator.
* have at least one traumatic wound meeting the criteria for closure as defined in current Dermabond product labeling.
* patient must be willing to follow instructions for wound care listed in device labeling and refrain from picking at the device, applying topical medications to the wound, and swimming or soaking in a tub until the sutures are removed.
* patient agrees to return for follow-up evaluation
* patient (or guardian) signs the informed consent
* patient is reasonably expected to survive the study

Exclusion Criteria

* significant multiple trauma (merely multiple wounds are allowed)
* peripheral vascular disease
* insulin dependent diabetes mellitus
* known to have a blood clotting disorder
* receiving antibiotic therapy for preexisting condition or infection
* known to be HIV-positive or otherwise immunocompromised
* known personal or family history of keloid formation or hypertrophy
* currently taking systemic steroids
* known allergy to cyanoacrylate, formaldehyde, tapes or adhesives
* participating in another current clinical study
* history of abnormal wound healing
* burst stellate lacerations due to a crush or hard blow
* animal or human bite or scratch
* decubitus ulcer
* puncture wound
* wound at mucocutaneous junction or in mucosal (but not excluding the vermillion border of the lip)
* wound on scalp covered by natural hair
* wound has visual evidence of active infection
* gangrenous wound
* wound requiring debridement of devitalized or contaminated tissue
* wound at site of active rash/skin lesion making evaluation difficult
* previously treated wound or has failed to heal
* wound in high skin tension area or across an area of increased skin tension, such as knuckles, elbows, or knees, unless the joint will be immobilized during the skin healing period or unless skin tension has been removed by application
Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ethicon, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Helen Colquhoun, MD

Role: STUDY_DIRECTOR

Pleiad Devices

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NextCare Institute For Clinical Research

Phoenix, Arizona, United States

Site Status

Orlando Regional Healthcare System

Orlando, Florida, United States

Site Status

Investigators Research Group, LLC

Indianapolis, Indiana, United States

Site Status

Tulane Universtiy Hospital & Clinic

New Orleans, Louisiana, United States

Site Status

Stony Brook University HSC

Stony Brook, New York, United States

Site Status

Duke University Health System

Durham, North Carolina, United States

Site Status

Wake Forest University Baptist Medical Center

Winston-Salem, North Carolina, United States

Site Status

Drexel University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IDE Number:G060268

Identifier Type: OTHER

Identifier Source: secondary_id

07CS005

Identifier Type: -

Identifier Source: org_study_id